Differential toxicities of albendazole and its two main metabolites to Balb/c 3T3, HepG2, and FaO lines and rat hepatocytes

Open access


Introduction: The cytotoxicity of anthelmintic agent, albendazole (ABZ) and its two major metabolites, sulfoxide (ABZSO) and sulfone (ABZ-SO2), on non-hepatic Balb/c 3T3 line, two hepatoma cell lines (FaO, HepG2), and isolated rat hepatocytes was investigated. Material and Methods: Cell cultures were exposed for 24, 48, and 72 h to eight concentrations of the compounds ranging from 0.05 to 100 μg/mL (ABZ) and from 0.78 to 100 μg/mL (ABZ-SO and ABZ-SO2). Three different assays were applied in which various biochemical endpoints were assessed: lysosomal activity - neutral red uptake (NRU) assay, proliferation - total protein contents (TPC) assay and lactate dehydrogenase (LDH) leakage assay. Results: The most toxic was albendazole whose EC50 values calculated from the concentration effect curves ranged from 0.2 to 0.5 μg/mL (Balb/c 3T3 ) and from 0.4 to 73.3 μg/mL (HepG2). Rat hepatoma line and isolated rat hepatocytes were less sensitive to the impact of ABZ. Toxic action expressed as EC50 was recorded after 72 h exposure only in LDH release assay at 0.8 μg/mL and 9.7 μg/mL respectively. The toxicity of metabolites was much lower. The most sensitive to ABZ-SO were fibroblasts and EC50-72h values were similar in all three assays used, i.e. NRU (14.1 μg/mL), TPC (15.8 μg/mL), and LDH (20.9 μg/mL). In the case of ABZ-SO2 the mean effective concentrations were the highest, and could be reached only in one LDH assay. These values (μg/mL) were as follows: 65.3 (FaO), 65.4 (HepG2), 75.8 (hepatocytes), and 77.4 (Balb/c 3T3). Conclusion: The differences in in vitro toxicity of albendazole depend on metabolic ability of the cellular models. Primary cultured rat hepatocytes represent a valuable tool to study the impact of biotransformation on the cytotoxicity of drugs.

1. Baliharová V., Skálova L., Maas R.F.M., De Vrieze G., Bull S., Fink-Gremmels J.: The effects of benzimidazole anthelmintics on P4501A in rat hepatocytes and HepG2 cells. Res Vet Sci 2003, 75, 61-69.

2. Blaauboer B.J., Boobis A.R., Castell J.V., Coecke S., Groothuis G.M.M., Guillouzo A., Hall T.J., Hawksworth G.M. Lorenzon G., Miltenburger H.G., Rogiers V., Skett P., Viia P., Wiebel F.J.: The practical applicability of hepatocyte cultures in routine testing. ECVAM Workshop Report 1. ATLA 1994, 22, 231-241.

3. Borenfreund E., Puerner J.A.: Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 1985, 24, 119-124.

4. Bradford M.M.: A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of dye binding. Anal Biochem 1976, 72, 248-254.

5. Campbell W.C.: Benzimidazoles: veterinary uses. Parasitol Today 1990, 6, 130-133.

6. Capleton A.C., Courage C., Rumsby P., Holmes P., Stutt E., Boxall A.B.A., Levy L.S.: Prioritising veterinary medicines according to their potential indirect human exposure and toxicity profile. Toxicol Lett 2006, 163, 213-223.

7. Carlsson G., Patring J., Ulleras E., Oskarsson A.: Developmental toxicity of albendazole and its three main metabolites in zebrafish embryos. Reprod Toxicol 2011, 32, 129-137.

8. Cristòfol C., Navarro M., Franquelo C., Valladares J.E., Carretero A., Ruberte J., Arboix M.: Disposition of netobimin, albendazole, and its metabolites in the pregnant rat: developmental toxicity. Toxicol Appl Pharmacol 1997, 144, 56-61.

9. Delatour P. Some aspects of the teratogenicity of veterinary drugs. Vet Res Commun 1983, 7, 125-131.

10. Donato M.T., Lahoz A., Castell J.V., Gómez-Lechón M.J.: Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 2008, 9, 1-11.

11. Donato M.T., Jover R., Gómez- Lechón M. J.: Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr Drug Metab 2013, 14, 946-968.

12. Eckardt K., Kaltenhauser J., Kilb C., Seiler A., Stahlmann R.: Relative potency of albendazole and its sulfoxide metabolite in two in vitro tests for developmental toxicity: the rat whole embryo culture and the mouse embryonic stem cell test. Reprod Toxicol 2012, 34, 378-384.

13. European Medicines Agency (EMEA). 2004. Committee for medicinal products for veterinary use. Albendazole - Summary Report (3). Available from: http://www.emea.eu.int.

14. Fotakis G., Timbrell J.A.: In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 2006, 160, 171-177.

15. Gerets H.H.J., Hanon E., Cornet M., Dhalluin S., Depelchin O., Canning M., Atienzar F.A.: Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. Toxicol in Vitro 2009, 23, 319-332.

16. Ivanova L., Uhlig S.: A bioassay for the simultaneous measurement of metabolic activity, membrane integrity, and lysosomal activity in cell cultures. Anal Biochem 2008, 379, 16-19.

17. Korzeniewski C., Calleawert D.M.: An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983, 64, 313-320.

18. Mattsson A., Ulleras E., Patring J., Oskarsson A.: Albendazole causes stage-dependent developmental toxicity and is deactivated by mammalian metabolization system in a modified zebrafish embryotoxicity test. Reprod Toxicol 2012, 34, 31-42.

19. Martin R.J.: Models of action of anthelmintic drugs. Vet J 1997, 154, 11-34.

20. Pohjala L., Tammela P., Samanta S.K., Yli-Kauhaluoma J., Vuorela P.: Assessing the data quality in predictive toxicology using a panel of cell lines and cytotoxicity assays. Anal Biochem 2007, 362, 221-228.

21. Pourgholami M.H., Woon L., Almajd R., Akhter J., Bowery P., Morris D.L.: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001, 165, 43-49.

22. Rico A.G., Burgat-Sacaze V.: Veterinary drugs and food safety: a toxicological approach. Rev sci tech Off int Epiz 1985, 4, 111-119.

23. Rolin S., Souhaili-ei Amri H., Batt A.M., Levy M., Baqrel D., Siest G.: Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatoma cell lines. Cell Biol Toxicol 1989, 5, 1-14.

24. Scheers E.M., Ekwall B., Dierickx P.J.: In vitro long-term cytotoxicity testing of 27 MEIC chemicals on HepG2 cells and comparison with acute human toxicity data. Toxicol in Vitro 2001, 15, 153-161.

25. Seglen P.O.: Preparation of isolation rat liver cells. Methods Cells Biol 1976, 13, 29-83.

26. Wang K., Shindoh H., Inoue T., Horii I.: Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell line. J Toxicol Sci 2002, 27, 229-237.

27. Weyermenn J., Lohmann D., Zimmer A.: A practical note on the use of cytotoxicity assays. Int J Pharm 2005, 288, 369-376.

28. Whittaker S.G., Faustman E.M.: Effects of albendazole and albendazole sufoxide on cultures of differentiating rodent embryonic cells. Toxicol Appl Pharmacol 1991, 109, 73-84.

29. Wilk-Zasadna I., Bernasconi C., Pelkonen O., Coecke S.: Biotransformation in vitro: an essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data. Toxicology 2015, 332, 8-19.

Journal of Veterinary Research

formerly Bulletin of the Veterinary Institute in Pulawy

Journal Information

IMPACT FACTOR J Vet Res 2017: 0.811

CiteScore 2017: 0.68

SCImago Journal Rank (SJR) 2017: 0.29
Source Normalized Impact per Paper (SNIP) 2017: 0.484

Cited By


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 151 135 3
PDF Downloads 83 81 3